Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15703724 | 0.88 | HCRTR1 (0.55) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18711482 | 0.79 | NPC1 (0.74) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL19617684 | 0.79 | MAPT (0.71) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10721898 | 0.77 | MAPK1 (0.85) | SMN1; SMN2LMNAALDH1A1MAPK1TSHR | |
| SCHEMBL18701805 | 0.76 | NPC1 (1.00) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4097883 | 0.75 | NPC1 (0.67) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24937772 | 0.75 | NPC1 (0.64) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL15940856 | 0.75 | NPC1 (0.80) | NPC1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3590893 | 0.75 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1MAPK1TSHRSLC6A7 | |
| SCHEMBL3819990 | 0.75 | SLC6A7 (1.00) | MAPTALDH1A1MAPK1TSHRSLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893212-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006124748-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | claimed |
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-1893212-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-2089018-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008067121-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1893212-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124748-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | NPC1 56/4885MAPT 41/4885SMN1; SMN2 878/4885 |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | NPC1 76/4885MAPT 7/4885SMN1; SMN2 614/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | NPC1 308/4885MAPT 101/4885SMN1; SMN2 1292/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | NPC1 256/4885MAPT 9/4885SMN1; SMN2 31/4885 |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | GRIN2C, CHAT, COMT | NPC1 56/4885MAPT 41/4885SMN1; SMN2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.